sur Galimedix, Inc.
Galimedix Therapeutics Advances Alzheimer's Development Strategy at CTAD 2026
Galimedix Therapeutics, a Phase 2 biotechnology firm, revealed its plans for developing GAL-101 for Alzheimer's at the CTAD 2026 in Boston. The company aims to establish GAL-101's efficacy in Down syndrome-associated Alzheimer's disease, while also advancing trials in the general Alzheimer's population through a Phase 2a biomarker-driven study named SAPHARY.
This study will enroll 100 patients with mild to moderate Alzheimer's to evaluate GAL-101's safety, efficacy, and pharmacokinetics/predictive dynamics parameters. The test will analyze EEG readouts, fluid biomarkers, and cognition endpoints. Pre-clinical results show GAL-101 can target and eliminate toxic amyloid beta species linked to neurodegenerative diseases, offering potential symptomatic relief without causing major side effects.
GAL-101's development extends to other conditions like dry age-related macular degeneration and glaucoma. Galimedix's strategic approach aims at offering new viable treatments for diseases with limited options.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Galimedix, Inc.